One in three patients who die in the U.S. dies of sepsis, according to the Centers for Disease Control and Prevention. It is one of the leading causes of death in intensive care units and, with an estimated price tag of $20 billion in 2011, the most expensive condition that hospitals treat.
Researchers at the Medical University of South Carolina (MUSC) found that sepsis outcomes in a preclinical model significantly improved when a microRNA (miRNA), specifically miR-126, which is known to protect against sepsis, was delivered via a nanocarrier. Almost 67 percent of mice treated with one of the nanocarrier/miR-126 complexes were still alive at seven days vs. just 25 percent of untreated mice. Their findings were reported in an article published online on September 23, 2018 in Inflammation.
"The exciting part is that we can use nanoparticles as a delivery system to carry microRNAs. It's feasible--we can do this," says Hongkuan Fan, Ph.D., senior author of the article and an assistant professor in the Department of Pathology and Laboratory Medicine at MUSC who studies vascular dysfunction in sepsis.
Sepsis is an overreaction of the body's immune system to an infection. Chemicals called cytokines flood the bloodstream in an attempt to fight the infection but also cause blood vessels to become leaky. White blood cells escape from the vessels, causing inflammation and damage to surrounding tissue, ultimately leading to multi-organ failure and death.
MicroRNAs are noncoding RNAs that are being assessed for therapeutic use in cancer and other diseases because they can prevent messenger RNA from creating proteins that can harm the body. Previous research by Fan's group has shown that an miRNA -- miR-126 -- is protective against sepsis. It is a major component of the fluid-filled sacs produced by endothelial progenitor cells. Fan's group has also shown that these cells, which regenerate the lining of blood vessels, help protect against the vascular damage caused by sepsis.
One obstacle to the clinical use of miRNAs, however, are ribonucleases (RNases), whose job it is to seek out and destroy them. Naturally occurring miRNAs are protected from RNases by a fluid-filled sac that covers them or a protein to which they are attached, but those introduced therapeutically have no such protection.
"If we were to just put an unprotected micro-RNA into the body, then it would immediately get chewed up by RNases," explains Joy N. Jones Buie, Ph.D., MSCR, a postdoctoral fellow at MUSC and the first author on the article. "So that's why you have to have some type of vehicle system to deliver the micro-RNA. Otherwise, if it's exposed to all these enzymes, it will immediately be destroyed."
The MUSC researchers showed that a proprietary nanocarrier (DEAC-pGlcNAc; Marine Polymer Technologies [Burlington, MA]) could deliver miR-126 effectively in a mouse model of sepsis, protecting it against damage by RNases. Its small size prevented its elimination by the liver, and its electrical charge was such that it was easily taken up by cells. The researchers were also able to verify that the nanoparticle successfully delivered miR-126 into the cell's nucleus by tagging it with a fluorescent dye.
"We could actually see them together using the microscope," says Jones Buie. "That showed that the micro-RNA was actually getting into the cell and associating with the cell's nucleus."
The mIR-126/nanocarrier complex more than doubled the proportion of mice alive at seven days vs. untreated mice in a preclinical model of sepsis (almost 67 percent vs. 25 percent). The nanoparticle, which has antibacterial properties, improved survival even when not complexed with miR-126, though not to a significant degree.
"Based on this and our previous studies, we know that targeted delivery of miR-126 has some therapeutic effect in a preclinical model of sepsis," says Fan. "Something is working, and that is exciting in a condition as severe and complicated as sepsis. We think that miR-126 has a promising future and will continue to explore it as well as the use of nanocarriers and other vehicles for its delivery."
This research was supported by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS), grant UL1 TR 001450, awarded to The South Carolina Clinical and Translational Research (SCTR) Institute, as well as other NIH funding. The study's findings are solely the responsibility of the authors and do not necessarily represent the official views of the NIH or NCATS. Financial and technical support were provided by Marine Polymer Sciences.
Founded in 1824 in Charleston, The Medical University of South Carolina is the oldest medical school in the South. Today, MUSC continues the tradition of excellence in education, research, and patient care. MUSC educates and trains more than 3,000 students and residents, and has nearly 13,000 employees, including approximately 1,500 faculty members. As the largest non-federal employer in Charleston, the university and its affiliates have collective annual budgets in excess of $2.2 billion. MUSC operates a 700-bed medical center, which includes a nationally recognized Children's Hospital, the Ashley River Tower (cardiovascular, digestive disease, and surgical oncology), Hollings Cancer Center (a National Cancer Institute-designated center) Level I Trauma Center, and Institute of Psychiatry. For more information on academic programs or clinical services, visit musc.edu. For more information on hospital patient services, visit muschealth.org.
About the South Carolina Clinical and Translational Research (SCTR) Institute
The South Carolina Clinical and Translational Research (SCTR) Institute, a National Institutes of Health Clinical and Translational Science Awards hub, is the catalyst for changing the culture of biomedical research, facilitating sharing of resources and expertise, and streamlining research-related processes to bring about large-scale, change in the clinical and translational research efforts in South Carolina. Our vision is to improve health outcomes and quality of life for the population through discoveries translated into evidence-based practice.